Healthcare | September 26, 2022
Alkem to spread awareness through “The Healthy Lungs”
Though lungs do not have the celebrity status as the heart, they are one of the most important and delicate organs of the human body
Though lungs do not have the celebrity status as the heart, they are one of the most important and delicate organs of the human body
This partnership aims to embed latest technological advancements in diagnosing and managing lung disorders and associated non-communicable diseases like asthma, pulmonary fibrosis and COPD.
Based on DESTINY-Lung02 results which showed AstraZeneca and Daiichi Sankyo’s Enhertu reported a confirmed objective response rate of 57.7% in patients with HER2-mutant disease
Patritumab deruxtecan is a specifically designed potential first-in-class HER3 directed antibody drug conjugate (ADC) discovered and being developed by Daiichi Sankyo.
DS-7300 is a specifically designed potential first-in-class B7-H3 directed antibody drug conjugate
Tabrecta is the number one prescribed targeted therapy for advanced NSCLC with alterations leading to METex14 skipping globally
Acceptance based on results from the phase 3 KEYNOTE-091 trial
Innate to receive $5M milestone payment from AstraZeneca
Lung cancer is the leading cause of cancer death in the USA, making up almost 25% of all cancer deaths
Potential new treatment for progressive pulmonary fibrosis (PPF) builds on Boehringer Ingelheim’s leadership in lung fibrosis and will be further investigated in a phase III clinical trial program
Subscribe To Our Newsletter & Stay Updated
